RESULTS	Three volunteers experienced adverse events ( AEs ) that were considered possibly related to gefitinib ( pruritus and dry skin ) , and 6 volunteers experienced procedure-related AEs ( cannula-site reaction and rhinorrhea ) ; these AEs were mild or moderate .\